Gubra A/s · OMXCOP:GUBRA
Gubra A/s — Q1 2024 Earnings Presentation
22 slides from Gubra A/s's earnings presentation, May 7, 2024
Slide 1: Q1-2024 investor presentation
Q1-2024 RESULTS Share ticker: Gubra NASDAQ Copenhagen Q1-2024 investor presentation 7 May 2024 Present from Gubra: Henrik Blou, CEO Niels Vrang, CSO Kristian Borbos, CFO Investor conference call 7 May 2024, 10:00am CET Follow live via: Gubra earnings release Q1-2024 - Q4 (q4inc.com) Dial-in numbers:
Slide 2: Forward looking statements
Forward looking statements Matters discussed in this presentation may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and that can be identified by words such as “believe“, “expect“, “anticipate“, “intends“, “estimate“, “will“, “may“, “c
Slide 3: The Gubra Hybrid Business Model
~220 Employees Dec 2023 The Gubra Hybrid Business Model 53% CRO revenue from the US CRO Discovery & 2023 Services Partnerships Specialized pre-clinical Discovery, design and contract research and development of 30% development services peptide-based drug Yearly revenue growth (CAGR) for the pharma a
Slide 4: Recent key highlights
Recent key highlights CRO business: • High revenue growth Q1-2024: Up 51% y/y • Obesity main growth driver D&P business: • Amylin Phase 1 study progressing according to plan (enrolment of key cohorts expected by mid-2024) • UCN2 asset for healthy weight loss progressing to preclinical tox Gubra comp
Slide 5: Our CRO business
CRO business OVERVIEW OF GUBRA’S DISEASE AREAS AND SERVICE OFFERING Our CRO business 3D Imaging Diabetes Liver Lungs Heart • Specialised in the pre-clinical phase with a (NASH/MASH) (CVD) stronghold in metabolic and fibrotic diseases • Highly ranked translatable rodent models 2D Histology • End-to-e
Slide 6: CRO business Q1-2024 results
CRO business Revenue (organic) DKKm Q1-2024 results 51% 58.5 Revenue 38.7 • Strong organic growth – up 51% vs. Q1 2023 • Obesity main growth driver Q1-2023 Q1-2024 Earnings Adjusted EBIT* Adjusted EBIT-margin* DKKm • High profitable growth 39% 100% • Adjusted EBIT of DKK 22.6m – doubling vs. Q1 2023
Slide 7: The streaMLine platform for drug discovery
D&P business The streaMLine platform for drug discovery Our Discovery & Partnership business (D&P) • Discovery, design and development of peptide-based drug candidates • Through our streaMLine platform we can: • Accelerate clinical candidate identification • Enhance potential for stronger patent pro
Slide 8: R&D Pipeline
R&D Pipeline Currently tested in clinical trial NCT05751226 by Boehringer Ingelheim alone or given in Partnered and internal programs (Drug Discovery and onwards) combination with semaglutide or survodutide 5 Active Partnerships 3 in Clinical Development 8 Obesity Projects 8
Slide 9: GUBamy
GUBamy GUBamy Once-weekly amylin analogue for the treatment of obesity 9
Slide 10: GUBamy weight loss in obese rats: 4-week combination study
GUBamy weight loss in obese rats: 4-week combination study Relative body weight Key takeaways 105 Vehicle Lean Vehicle DIO • Additive weight loss in obese rats when Tirzepatide GUBamy was combined with GLP-1 95 Body weight (%) containing molecules: Semaglutide Survodutide GUBamy • Semaglutide (GLP-1
Slide 11: Phase 1 study First-In-Human
Phase 1 study First-In-Human ClinicalTrials.gov NCT06144684 Study setup • Randomized, placebo-controlled, single ascending dose trial • Assess safety, tolerability, pharmacokinetics, and pharmacodynamics of GUBamy • Lean to overweight, but otherwise healthy subjects Participants and timeframe • Up t
Slide 12: GUB-UCN2: High quality weight loss with once weekly UCN2 analogues
GUB-UCN2 High quality weight loss with Once weekly UCN2 analogues 12
Slide 13: Substantial weight loss with today's pharmacotherapy
Substantial weight loss with today's pharmacotherapy Body weight loss Composition of weight loss 2 Treatment Phase 100 0 90 Fat mass 2 80 Lean mass Lost weight (%) 4 Lost weight (%) 70 6 60 8 50 10 40 12 30 14 Placebo 20 16 18 Treatment 10 0 Time Lean mass accounts for 20-40 % of the weight lost Wei
Slide 14: Time to focus on healthy weight loss
Time to focus on healthy weight loss Treatment paradigm for future obesity treatment Healthy weight loss 100 Maximize loss of fat mass 90 Fat mass Lean mass 80 Lost weight (%) 70 60 While preserving/increasing lean mass 50 40 AIM 30 20 With potential cardiorenal upside 10 0 14
Slide 15: Selective long-acting UCN2 analogues
Selective long-acting UCN2 analogues Ready for development Selective receptor profile Excellent physical and Pharmacokinetics: chemical stability: + Allometric scaling from data in mouse, rat and minipig + No amyloid fibril formation support once-weekly dosing in humans + High chemical stability + H
Slide 16: Improved metabolic parameters with cardiorenal upside
Improved metabolic parameters with cardiorenal upside Pre-clinical data: (GUB-UCN2) Fat mass loss Improved kidney Improved heart/ Lean mass increase function cardiovascular function Improved glucose homeostasis ‘healthy weight loss’ 16
Slide 17: GUB-UCN2 increases lean mass and decreases fat mass in DIO rats
GUB-UCN2 increases lean mass and decreases fat mass dose-dependently in DIO rats Transient body weight loss Increased lean mass Decreased fat mass Relative body weight Lean mass change from baseline Fat mass change from baseline 120 Fat mass change from baseline (g) Lean mass change from baseline (g
Slide 18: GUB-UCN2 eliminates lean mass loss induced by other anti-obesity agents
GUB-UCN2 eliminates lean mass loss induced by other anti-obesity agents in DIO rats Sustained body weight Increased lean mass Decreased fat mass Relative body weight Lean mass change from baseline Fat mass change from baseline 110 Lean mass change from baseline (g) Fat mass change from baseline (g)
Slide 19: D&P business Q1-2024 results
D&P business Total adjusted costs* Revenue DKKm DKKm Q1-2024 results 33.2 11.2 • Decrease in partnership revenue vs. Q1 2023 29.0 6.5 • Total costs increasing slightly due to increase in headcounts Q1-2023 Q1-2024 Q1-2023 Q1-2024 Adjusted EBIT* DKKm -17.7 -26.6 Q1-2023 Q1-2024 * For Gubra Group, tot
Slide 20: Gubra Green
Gubra Green Nature Positive and Carbon Negative Gubra Green GUBRA GREEN • We are investing 10% of pretax profit from Gubra A/S into Gubra Green on green initiatives 90% OF RETURNS PASSIVE INVESTMENTS ONLY generated in Gubra Green will be to ensure that limited resources • Gubra Green is a fully owne
Slide 21: Financial outlook and guidance
Financial outlook and guidance New outlook Previous outlook Results Mid-term Guidance items 20243 2024 Q1 2024 guidance CRO segment Organic revenue growth 15-20% 10-15% 51% 10% annually Adjusted EBIT-margin1 28-31% 25-28% 39% 35-40% Discovery & Partnership segment Number of new partnerships per year
Slide 22: Thank you for your attention!
Thank you for your attention! Gubra A/S Hørsholm Kongevej 11B DK-2970 Hørsholm Denmark www.gubra.dk Let’s stay connected 22